Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 7

Results For "antibodies"

246 News Found

DBT, BIRAC and CEPI renew cooperation agreement for vaccine development
R&D | December 05, 2025

DBT, BIRAC and CEPI renew cooperation agreement for vaccine development

DBT and BIRAC have partnered with CEPI since 2019, for cooperation on vaccine development for diseases of epidemic potential


GV20 Therapeutics hits milestone in AI-driven cancer therapy collaboration with Mitsubishi Tanabe Pharma
News | November 28, 2025

GV20 Therapeutics hits milestone in AI-driven cancer therapy collaboration with Mitsubishi Tanabe Pharma

GV20 received an upfront payment and is eligible for additional milestone payments


FDA investigates fatal case linked to rare blood disorder drug Adzynma
News | November 24, 2025

FDA investigates fatal case linked to rare blood disorder drug Adzynma

Adzynma, approved for both adults and children with cTTP, is a recombinant enzyme therapy designed to replace the deficient ADAMTS13 enzyme


Orion secures license to Abzena’s next-generation cancer antibody
R&D | October 29, 2025

Orion secures license to Abzena’s next-generation cancer antibody

The antibody was designed and developed at Abzena’s Cambridge, UK,


Novartis to acquire Avidity Biosciences for $12 billion
Biotech | October 27, 2025

Novartis to acquire Avidity Biosciences for $12 billion

The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company


Merck KGaA  to acquire chromatography business of JSR Life Sciences
News | October 16, 2025

Merck KGaA to acquire chromatography business of JSR Life Sciences

Acquisition aims to strengthen Merck's downstream process offering of advanced filtration and chromatography solutions


Lonza receives Swissmedic approval for Biologics drug product filling line in Stein
News | October 09, 2025

Lonza receives Swissmedic approval for Biologics drug product filling line in Stein

New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain